title: Immunotherapy with Tolerogenic Dendritic Cells Alone or in Combination with Rapamycin Does Not Reverse Diabetes in NOD Mice.
abstract: Type 1 diabetes is a metabolic disease caused by autoimmunity towards β -cells. Different strategies have been developed to restore β -cell function and to reestablish immune tolerance to prevent and cure the disease. Currently, there is no effective treatment strategy to restore endogenous insulin secretion in patients with type 1 diabetes. This study aims to restore insulin secretion in diabetic mice with experimental antigen-specific immunotherapy alone or in combination with rapamycin, a compound well known for its immunomodulatory effect. Nonobese diabetic (NOD) mice develop spontaneous type 1 diabetes after 12 weeks of age. Autologous tolerogenic dendritic cells-consisting in dendritic cells pulsed with islet apoptotic cells-were administered to diabetic NOD mice alone or in combination with rapamycin. The ability of this therapy to revert type 1 diabetes was determined by assessing the insulitis score and by measuring both blood glucose levels and C-peptide concentration. Our findings indicate that tolerogenic dendritic cells alone or in combination with rapamycin do not ameliorate diabetes in NOD mice. These results suggest that alternative strategies may be considered for the cure of type 1 diabetes.
authors.affiliation: Laboratory of Immunobiology for Research and Diagnosis (LIRAD-BST), Germans Trias i Pujol Research Institute, Autonomous University of Barcelona, 08916 Badalona, Spain.
authors.forename: Irma
authors.initials: I
authors.lastname: Pujol-Autonell
authors.forename: Rosa M
authors.initials: RM
authors.lastname: Ampudia
authors.forename: Pau
authors.initials: P
authors.lastname: Monge
authors.forename: Anna M
authors.initials: AM
authors.lastname: Lucas
authors.forename: Jorge
authors.initials: J
authors.lastname: Carrascal
authors.forename: Joan
authors.initials: J
authors.lastname: Verdaguer
authors.forename: Marta
authors.initials: M
authors.lastname: Vives-Pi
references.citation: Clin Exp Immunol. 2010 May;160(2):207-14
references.pmid: 20030670
references.citation: J Immunol. 1997 Mar 15;158(6):2947-54
references.pmid: 9058834
references.citation: Cell Transplant. 2009;18(8):833-45
references.pmid: 19500470
references.citation: J Nephrol. 2004 Nov-Dec;17(6):762-8
references.pmid: 15593048
references.citation: Diabetes. 2008 Sep;57(9):2341-7
references.pmid: 18559659
references.citation: Immunity. 2005 Aug;23(2):115-26
references.pmid: 16111631
references.citation: Annu Rev Immunol. 2001;19:131-61
references.pmid: 11244033
references.citation: Immunity. 2010 Apr 23;32(4):568-80
references.pmid: 20381385
references.citation: Diabetes. 1991 Jul;40(7):842-9
references.pmid: 1647994
references.citation: Diabetes. 2009 Apr;58(4):875-81
references.pmid: 19151201
references.citation: Diabetes. 2002 Mar;51(3):638-45
references.pmid: 11872661
references.citation: Expert Rev Clin Immunol. 2010 Nov;6(6):939-55
references.pmid: 20979558
references.citation: Clin Exp Immunol. 1992 Aug;89(2):174-8
references.pmid: 1638761
references.citation: Nat Med. 2003 Sep;9(9):1202-8
references.pmid: 12937416